Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose triple therapy for Helicobacter pylori eradication: 10 days versus 14 days
IRCT20131124015510N7Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of esomeprazole, amoxicillin and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Helicobacter pylori eradication rate, Drug side effects and 1 more. Started Feb 2026; status: completed.
02
Drugs
esomeprazoleamoxicillinbismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20131124015510N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20131124015510N7.